What does SpliceBio do?
SpliceBio is a Barcelona-based clinical-stage genetic medicines company that uses protein splicing technology to develop therapies for diseases caused by mutations in large genes. Its pipeline includes a lead gene therapy candidate, SB-007, targeting Stargardt disease, as well as other programs in ophthalmology and neurology.
How much did they raise?
The company raised $135M in its Series B round, led by EQT Life Sciences and Sanofi Ventures with participation from Roche Venture Fund, New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.
What are their plans for the money?
The funds will be used to advance the clinical development of SB-007, including supporting the ongoing interventional Phase 1/2 ASTRA study and the observational POLARIS study. This could accelerate the availability of novel treatments for Stargardt disease and expand the company’s pipeline of genetic medicines.
What have they achieved so far?
SpliceBio has made significant progress with its lead candidate SB-007, having initiated the Phase 1/2 ASTRA study and conducting the observational POLARIS study, reflecting its commitment to addressing the root causes of genetic diseases.
